OR WAIT 15 SECS
The Cambridge Design Partnership and the Stevanato Group have announced a partnership that will see the development of a new pen-injector based on the Axis-D technology and IP licensed from Haselmeier in 2019.
The Cambridge Design Partnership (CDP) and the Stevanato Group have announced a partnership that will see the development of a new pen-injector based on the Axis-D technology and intellectual property (IP) licensed from Haselmeier in 2019.
According to an April 28, 2020 press release, the collaboration supports the expansion of the portfolio of products for diabetes patients from the Stevanato Group. Leveraging the design and development expertise of CDP with Stevanato Group’s experience in glass containers, tooling, injection molding, device assembly, and global commercial network, the partnership will offer pharma customers drug delivery solutions from first concept to commercial-scale production.
“We are delighted to be announcing this partnership,” said Uri Baruch, CDP’s head of Drug Delivery, in the press release. “The Stevanato Group is well established in the device field as a leading supplier of cartridges and assembly equipment for pen-injectors. It is a pleasure to extend our existing working relationship with them for their pen-injector and to address the needs of patients.”
“Our R&D team-with the active support of CDP, an established player in the design and development of drug delivery devices-will offer a competitive pen-injector platform and some customization options,” added Paolo Patri, chief technology officer at the Stevanato Group, in the press release. “With the resources and experience of both companies, we will provide diabetic patients with a product that is easy-to-use, aesthetically appealing, and cost-effective.”